What it is
GLOW is a three-peptide research blend combining GHK-Cu, BPC-157 and TB-500. It is essentially KLOW without the KPV component, and is marketed toward skin appearance, recovery and tissue repair. Like KLOW, it is sold strictly as a research chemical, labelled "for research use only, not for human consumption."
The three components
- GHK-Cu — copper tripeptide, the best-evidenced of the three for topical skin and collagen synthesis. See full page
- BPC-157 — tissue-repair peptide with mostly animal evidence; not approved, banned in sport. See full page
- TB-500 — thymosin beta-4 fragment studied for cell migration and angiogenesis; mostly animal data. See full page
The theory behind the blend
The pitch is that GHK-Cu drives collagen and skin remodelling while BPC-157 and TB-500 support tissue repair and blood-vessel formation, giving a combined "skin plus recovery" effect. It is a plausible-sounding rationale built on each peptide's individual proposed mechanism, but the combination has not been tested for either effectiveness or safety in humans.
GLOW vs KLOW
The practical difference is one ingredient: KLOW adds KPV, an anti-inflammatory tripeptide, to the GLOW base. Both are untested as blends. Neither additional ingredient nor the act of combining them changes the fundamental position: these are research chemicals without human trials behind the formulation.
Where it stands
GLOW is a marketed combination of three unapproved peptides. Of its parts, only GHK-Cu has solid human evidence, and that is for topical use rather than injection of a blend. There is no efficacy or safety data on GLOW itself. It belongs firmly in the research-only category.